OBJECTIVE: Ataxia telangiectasia (AT) is a rare genetic, multi-system disorder characterized by neurodegeneration, chromosome instability, B and T cell immunodeficiency and a predisposition to cancer. We examined immunologic parameters reflecting cell development and proliferation and their relevancy to the clinical phenotype in affected individuals. PATIENTS AND METHODS: AT patients from the AT National Clinic in Israel underwent immunological investigation. Their T and B cell workup included lymphocyte subset counts, immunoglobulin levels, responses to mitogenic stimulations, TCR-Vβ families and BCR immunoglobulin heavy chain spectratyping, TCR rearrangement excision circles (TRECs) and Kappa-deleting recombination excision circles (KRECs). RESULTS: Thirty-seven AT patients (median age 12.7 years, range 4.2-25.1) were evaluated. CD20 B and CD3 T lymphocytes were decreased in 67 % and 64 % of the patients, respectively, while only 33 % of the patients had reduced lymphoproliferative responses. Almost all AT patients displayed extremely low TRECs and KRECs levels, irrespective of their age. Those levels were correlated to one another and to the amounts of CD3+ and CD20+ cells, respectively. Abnormal TCR-Vβ repertoires were found with different degrees of clonality or reduced expression in these AT patients. There was no clear clustering of expansions to specific TCR-Vβ genes. PCR spectratyping analysis of the FR2 IgH BCR gene rearrangements in peripheral blood was abnormal in 50 % of the patients. CONCLUSION: The immunodeficiency associated with AT is combined, remains low over time and not progressive. It is characterized by low TREC and KREC copies suggestive of abnormal T and B cell neogenesis.
OBJECTIVE:Ataxia telangiectasia (AT) is a rare genetic, multi-system disorder characterized by neurodegeneration, chromosome instability, B and T cell immunodeficiency and a predisposition to cancer. We examined immunologic parameters reflecting cell development and proliferation and their relevancy to the clinical phenotype in affected individuals. PATIENTS AND METHODS: AT patients from the AT National Clinic in Israel underwent immunological investigation. Their T and B cell workup included lymphocyte subset counts, immunoglobulin levels, responses to mitogenic stimulations, TCR-Vβ families and BCR immunoglobulin heavy chain spectratyping, TCR rearrangement excision circles (TRECs) and Kappa-deleting recombination excision circles (KRECs). RESULTS: Thirty-seven AT patients (median age 12.7 years, range 4.2-25.1) were evaluated. CD20 B and CD3 T lymphocytes were decreased in 67 % and 64 % of the patients, respectively, while only 33 % of the patients had reduced lymphoproliferative responses. Almost all AT patients displayed extremely low TRECs and KRECs levels, irrespective of their age. Those levels were correlated to one another and to the amounts of CD3+ and CD20+ cells, respectively. Abnormal TCR-Vβ repertoires were found with different degrees of clonality or reduced expression in these AT patients. There was no clear clustering of expansions to specific TCR-Vβ genes. PCR spectratyping analysis of the FR2 IgH BCR gene rearrangements in peripheral blood was abnormal in 50 % of the patients. CONCLUSION: The immunodeficiency associated with AT is combined, remains low over time and not progressive. It is characterized by low TREC and KREC copies suggestive of abnormal T and B cell neogenesis.
Authors: Ilja Demuth; Véronique Dutrannoy; Wilson Marques; Heidemarie Neitzel; Detlev Schindler; Petja S Dimova; Krystyna H Chrzanowska; Veneta Bojinova; Hanna Gregorek; Luitgard M Graul-Neumann; Arpad von Moers; Ilka Schulze; Marion Nicke; Elcin Bora; Tufan Cankaya; Éva Oláh; Csongor Kiss; Beáta Bessenyei; Katalin Szakszon; Ursula Gruber-Sedlmayr; Peter Michael Kroisel; Sigrun Sodia; Timm O Goecke; Thilo Dörk; Martin Digweed; Karl Sperling; Joaquim de Sá; Charles Marques Lourenco; Raymonda Varon Journal: Neurogenetics Date: 2011-10-02 Impact factor: 2.660
Authors: Jacob Mallott; Antonia Kwan; Joseph Church; Diana Gonzalez-Espinosa; Fred Lorey; Ling Fung Tang; Uma Sunderam; Sadhna Rana; Rajgopal Srinivasan; Steven E Brenner; Jennifer Puck Journal: J Clin Immunol Date: 2012-12-20 Impact factor: 8.317
Authors: S Levy-Mendelovich; A Lev; E Rechavi; O Barel; H Golan; B Bielorai; Y Neumann; A J Simon; R Somech Journal: Clin Exp Immunol Date: 2017-06-05 Impact factor: 4.330
Authors: Ki L Milligan; Karen Schirm; Stephanie Leonard; Ashleigh A Hussey; Anahita Agharahimi; David E Kleiner; Ivan Fuss; Shilpa Lingala; Theo Heller; Sergio D Rosenzweig Journal: J Clin Immunol Date: 2016-09-26 Impact factor: 8.317
Authors: Rachel Warren; William Domm; Min Yee; Andrew Campbell; Jane Malone; Terry Wright; Margot Mayer-Pröschel; Michael A O'Reilly Journal: Am J Physiol Lung Cell Mol Physiol Date: 2019-09-11 Impact factor: 5.464